NFKB1 and breast cancer: To determine whether the ASA prodrugs we synthesized (Fig. 1a and Additional file 2: Figure S1) inhibit the NFκB pathway, their activity was screened in MCF-7 breast cancer cells at one dose (50 μM) on NFκB-RE and NFκB target gene endpoints (Fig. 1b-e).